ライフサイエンスコーパス: atenolol

1 r CAS (verapamil sustained release) or NCAS (atenolol).

2 th agonists given together with 1 micromol/L atenolol).

3 shed by the beta(1) -adrenoceptor antagonist atenolol.

4 baroreflex as it persists in the presence of atenolol.

5 reduce left ventricular (LV) mass more than atenolol.

6 after beta-adrenergic receptor blockade with atenolol.

7 e selective beta(1)-adrenoceptor antagonist, atenolol.

8 aily double-blind treatment with losartan or atenolol.

9 essure was reduced similarly by losartan and atenolol.

10 ion and to control his ventricular rate with atenolol.

11 eding, an effect abrogated by treatment with atenolol.

12 ine, isoprenaline, flecainide, verapamil and atenolol.

13 antidepressant venlafaxine, and beta-blocker atenolol.

14 st entirely on the conventional beta-blocker atenolol.

15 icated hypertension comes from studies using atenolol.

16 ainly by the emerging deleterious effects of atenolol.

17 Atenolol (0.1 microM), a selective beta1-AR antagonist,

18 er intravenous injections: saline (control), atenolol (0.2 mg/kg, beta-adrenergic blockade), atropine

19 Furthermore, atenolol (0.5 microg) blocked the memory-enhancing effec

20 nfusions of the beta-adrenoceptor antagonist atenolol (0.5 microgram in 0.2 microliter) into the ipsi

21 e-anaesthetized, artificially ventilated and atenolol (1 mg kg(-1))-pretreated cats.

22 captopril (25 mg/kg body weight per day) or atenolol (10 mg/kg body weight per day) for 8 weeks.

23 The selective beta 1-adrenergic antagonist atenolol (10(-6) M) did not affect terbutaline-induced d

24 In the second phase, atenolol 100 mg was added to amlodipine and isosorbide 5

25 ne 1.25 mg, hydrochlorothiazide 6.25 mg, and atenolol 12.5 mg).

26 ed-dose pill containing 5 mg ramipril, 50 mg atenolol, 12.5 mg hydrochlorothiazide, 20 mg simvastatin

27 ration was by dose doubling, and addition of atenolol 25-50 mg or enalapril 5-10 mg.

28 or matching placebo, and the step 2 drug is atenolol (25-50 mg) or matching placebo.

29 ent with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d) added if necessary to maintain goa

30 thalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d)

31 (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ram

32 s reduced by 25% with losartan compared with atenolol, 25.1 vs 35.4 events per 1000 patient-years (re

33 rothiazide (59% versus 34%, P<0.001) but not atenolol (27% versus 22%, NS).

34 t CVR improved with amlodipine compared with atenolol (-39.6 x 10(-4)%/mm Hg [95% CI -72.5 to -6.6; p

35 mg digoxin, 2) 240 mg diltiazem-CD, 3) 50 mg atenolol, 4) 0.25 mg digoxin + 240 mg diltiazem-CD, and

36 .6; p=0.019) and with losartan compared with atenolol (-43.3 x 10(-4)%/mm Hg [-74.3 to -12.3]; p=0.00

37 CAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide;

38 lowering drugs (hydrochlorthiazide, 12.5 mg; atenolol, 50 mg; ramipril, 5 mg) at low doses, simvastat

39 neal injection (metoprolol, 100 mg x kg(-1); atenolol, 6 mg x kg(-1)) or central nervous system beta1

40 goxin + diltiazem: 67.3+/-14.1 and digoxin + atenolol: 65.0+/-9.4.

41 oxin: 78.9 +/- 16.3, diltiazem: 80.0+/-15.5, atenolol: 75.9+/-11.7, digoxin + diltiazem: 67.3+/-14.1

42 beta-AR blockers (carvedilol, metoprolol, or atenolol), 9 from patients with heart failure without be

43 he lowest doses of rate-control medications; atenolol: 92 mg versus 68 mg; carvedilol: 44 mg versus 2

44 (a nonspecific beta-adrenergic antagonist), atenolol (a beta1-adrenergic antagonist), or zinterol (a

45 Neither atenolol, a beta 1-specific adrenergic antagonist, prazo

46 in secretion, and this effect was blocked by atenolol, a selective beta(1)-adrenergic antagonist.

47 Blockade of beta-adrenergic receptors with atenolol abolished the pup-induced heart rate increase,

48 etic blockade: Atropine, given alone or with atenolol, abolished nearly all RR-interval variability a

49 group (n=3294) included patients initiating atenolol, acebutolol, or metoprolol.

50 vironments for the further transformation of atenolol acid.

51 tenolol was transformed almost completely to atenolol acid.

52 2-propanolmethanesulphonate (CGP 20712A) and atenolol act as classic antagonists at the catecholamine

53 risk of 90-day postoperative mortality with atenolol [adj.

54 Inhibition was also seen following atenolol administration.

55 vere chronic angina taking standard doses of atenolol, amlodipine, or diltiazem, without evident adve

56 ffects of amlodipine, whereas the effects of atenolol and amlodipine were not additive.

57 fate (0.04 mg/kg, parasympathetic blockade), atenolol and atropine (complete autonomic blockade), and

58 and twice under combined autonomic blockade (atenolol and atropine sulfate) conditions.

59 Adizem XL) and the combination of amlodipine/atenolol and diltiazem (Adizem XL)/isosorbide 5-mononitr

60 Monitoring of transformation products of atenolol and emtricitabine confirmed that inhibition was

61 As expected, atenolol and hydrochlorothiazide correlated positively w

62 sociation studies may predict BP response to atenolol and hydrochlorothiazide when assessed through r

63 In vitro, similar to R(+) propranolol, both atenolol and its R(+) enantiomer inhibited HemSC to endo

64 rug (high stereoselectivity was recorded for atenolol and MDMA), treatment technology used (activated

65 Atenolol and metoprolol showed first-order elimination w

66 Nifedipine GITS, atenolol and placebo were administered to 15 subjects wi

67 rom trials of traditional beta-blockers (eg, atenolol and propranolol), because there are currently n

68 h adrenergic receptor modifiers: clenbuterol atenolol and SR59230A (IUGR-AR).

69 ion CT scanner after premedication with oral atenolol and/or intravenous metoprolol.

70 of 0.1-1.3 h(-1) for MCPA, 2,4-D, mecoprop, atenolol, and diclofenac, corresponding to half-lives of

71 of a variety of drugs including propranolol, atenolol, and ibuprofen has been developed.

72 tricular rate control, verapamil, diltiazem, atenolol, and metoprolol were qualitatively superior to

73 ive correlations with IRSAD, while tramadol, atenolol, and pregabalin had strong negative correlation

74 release compartments containing pravastatin, atenolol, and ramipril.

75 f a polypill containing aspirin, lisinopril, atenolol, and simvastatin for secondary prevention of at

76 rapidly degraded 1,4-dioxane, carbamazepine, atenolol, and sulfamethoxazole in RO permeate.

77 2.0 (SD 13.7) and 1.3 (SD 12.1) beats/min in atenolol- and amlodipine-based groups, respectively.

78 Both nifedipine GITS and atenolol are effective at preventing mental stress-induc

79 d by 28/9 and 28/9 mm Hg in the losartan and atenolol arms.

80 metabolic and genetic mechanisms underlying atenolol-associated adverse metabolic effects.

81 Atenolol at a concentration 1 mum inhibited the vasodila

82 al monotherapy with amlodipine, losartan, or atenolol at approved doses.

83 Ds were abolished by beta(1)-antagonism with atenolol at therapeutic concentration (1 mum).

84 norepinephrine (NE) alone (10 mcmol/L) or NE+atenolol (AT) (10 mcmol/L) for 12 hours.

85 wo challenging drugs (i.e., the beta-blocker atenolol (At) and the veterinary antibiotic sulfamethazi

86 y diclofenac (DCF), and the antihypertensive atenolol (At).

87 olymer (MIP)-based ultrathin film using R(+)-atenolol (ATNL) as a template was reported.

88 edical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placeb

89 tion drug regimen than in those allocated an atenolol-based combination drug regimen (HR 0.86 and 0.7

90 ct of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in

91 -up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly redu

92 approximately 1 year after randomization to atenolol-based or amlodipine-based antihypertensive trea

93 r in patients on the atenolol-based regimen: atenolol-based regimen, 7.9 +/- 1.8; amlodipine-based re

94 P) (mean +/- SD) was similar in both groups: atenolol-based regimen, systolic BP of 137 +/- 17 mm Hg,

95 olic function than patients treated with the atenolol-based regimen.

96 were significantly higher in patients on the atenolol-based regimen.

97 lic relaxation, was lower in patients on the atenolol-based regimen: atenolol-based regimen, 7.9 +/-

98 tension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG

99 PLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hyperten

100 er a verapamil sustained-release (SR)- or an atenolol-based strategy for blood pressure (BP) control.

101 ssigned to a verapamil sustained-release- or atenolol-based strategy; blood pressure control and outc

102 cated amlodipine-based therapy compared with atenolol-based therapy (unadjusted hazard ratio: 0.81, p

103 hat the superiority of amlodipine-based over atenolol-based therapy for patients with hypertension un

104 The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients wi

105 ective central aortic pressure lowering with atenolol-based therapy versus amlodipine-based therapy i

106 t and Sokolow-Lyon voltage criteria than did atenolol-based therapy.

107 tage (-2.5 versus -0.7 mm, P<0.001) than was atenolol-based therapy.

108 4, and 5 years of blinded losartan-based or atenolol-based therapy.

109 of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to

110 Losartan- or atenolol-based treatment regimens, with follow-up assess

111 Losartan- or atenolol-based treatment regimens, with follow-up assess

112 n in patients with ECG LVH than conventional atenolol-based treatment.

113 d amongst those allocated to amlodipine- and atenolol-based treatment.

114 mized to a mean of 4.8 years of losartan- or atenolol-based treatment.

115 ardiogram, randomly assigned to losartan- or atenolol-based treatment.

116 Nebivolol/bendrofluazide and atenolol/bendrofluazide each lowered the clinic blood pr

117 r the same degree of blood pressure control, atenolol/bendrofluazide had no effect on nitric oxide bi

118 ean+/-SEM], 435+/-27%, P<0.001) but not with atenolol/bendrofluazide.

119 a second experiment, intra-BLA infusions of atenolol (beta-adrenoceptor antagonist) and Rp-cAMPS (cA

120 oceptor antagonists (propranol, beta1/beta2; atenolol, beta1; ICI 118551; beta2; 100 microm), or by t

121 ng the four beta-blocker cohorts metoprolol, atenolol, bisoprolol and other beta-blockers.

122 were divided into four cohorts: metoprolol, atenolol, bisoprolol, and other beta-blockers.

123 artery disease on beta-blocker therapy with atenolol, bisoprolol, or metoprolol underwent adenosine

124 ficance (P<0.05), and 3 were associated with atenolol BP response at P<0.01.

125 The genetic score of the atenolol BP-lowering alleles was associated with respons

126 Atenolol but not BIBN4096bs increased contraction to EFS

127 antihypertensive drugs: hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem (sustained rel

128 g) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochloroth

129 g) were randomly allocated to treatment with atenolol, captopril, clonidine, diltiazem, hydrochloroth

130 librated using measured photolysis rates for atenolol, carbamazepine, propranolol, and sulfamethoxazo

131 ased significantly with hydrochlorothiazide, atenolol, clonidine, and diltiazem at 1 year and with al

132 t under systemic beta-adrenoceptor blockade (atenolol) combined with spinal cord (C1) transection (to

133 tions suggest inhibition is most relevant at atenolol concentrations greater than approximately 200 n

134 Propranolol and atenolol, current therapies for problematic infantile he

135 However, only metoprolol, but not atenolol, decreased binge-like alcohol drinking.

136 Results suggest that the role of AOB in atenolol degradation may be disproportionately more sign

137 eutical compounds loratadine, oxycodone, and atenolol deposited on glass, wood, steel, and polyester

138 resonant laser vaporization of oxycodone and atenolol desorbed from steel is 2.4% +/- 1.5% and 0.25%

139 Acetylsalicylic acid, acetaminophen, atenolol, diclofenac, and ibuprofen were tested as targe

140 Atenolol did not block the stimulatory effects of epinep

141 s of treatment with amlodipine, losartan, or atenolol did not differ in their effects on cerebrovascu

142 amlodipine +/- perindopril-based and 4275 to atenolol +/- diuretic-based treatment during the in-tria

143 At 1 year, use of added open-label atenolol, diuretics, angiotensin-converting enzyme inhib

144 er(II)-bound complexes of seven model drugs (atenolol, DOPA, ephedrine, pseudoephedrine, isoprotereno

145 beta1-adrenergic receptor (beta1AR) blocker atenolol during CSDS blunts the elevation of plasma acyl

146 t undergo noncardiac surgery, treatment with atenolol during hospitalization can reduce mortality and

147 riment 2), or the beta1-receptor antagonist, atenolol (Experiment 3).

148 nabling rapid 1H NMR spectral acquisition of atenolol (experimental time of 10 s) without obstruction

149 rhoea with dehydration) and one while taking atenolol (fall with fracture), neither of which was rela

150 sive Responses (PEAR) study and treated with atenolol for 9 weeks, we prospectively followed a nested

151 se data suggest that losartan is superior to atenolol for treatment of patients with isolated systoli

152 from 70% for hydrochlorothiazide to 92% for atenolol for younger white men, and from 84% for hydroch

153 The hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in

154 cITP successfully isolates the atenolol from the sucrose while concentrating it 200-fol

155 so lower in the amlodipine group than in the atenolol group (all p<0.0001).

156 t in the placebo group and 83 percent in the atenolol group (P=0.008).

157 e (mean [+/-SD] age, 11.5+/-6.5 years in the atenolol group and 11.0+/-6.2 years in the losartan grou

158 ore did not differ significantly between the atenolol group and the losartan group (-0.139+/-0.013 an

159 as lower in the amlodipine group than in the atenolol group at all follow-up visits (p<0.0001), mainl

160 sit variability in SBP were increased in the atenolol group compared with both the placebo group and

161 ty in blood pressure during follow-up in the atenolol group correlated with trends in stroke risk.

162 Ninety-nine were assigned to the atenolol group, and 101 to the placebo group.

163 in the amlodipine group and increased in the atenolol group.

164 Also, ICV administration of atenolol had no effect on peripheral endogenous ghrelin

165 .01) compared with the diabetic control, but atenolol had no significant effect.

166 dine, and amisulpride, while epinephrine and atenolol had the highest V(max).

167 strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertens

168 a treatment strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained

169 (verapamil) or beta-blocker/diuretic-based (atenolol/hydrochlorothiazide) antihypertensive care stra

170 .4 microL injection of 200 microM (1.9 nmol) atenolol in a 1000-fold excess of sucrose (200 mM) is an

171 atenolol) for the primary end point favored atenolol in black patients (1.666 [95% confidence interv

172 d a randomized trial comparing losartan with atenolol in children and young adults with Marfan's synd

173 mesoporous MCM-41, for prolonged release of atenolol in drug delivery systems was investigated both

174 conventional treatment with the beta-blocker atenolol in patients with hypertension and electrocardio

175 ar disease, losartan was more effective than atenolol in preventing cardiovascular morbidity and deat

176 mlodipine enhanced P-selectin expression and atenolol increased fibrinogen binding in response to ago

177 Atenolol inhibited both responses (SSS, P = 0.003; L-glu

178 d beta-blockers and increased over time, and atenolol initiation decreased over time.

179 fusions of the beta1-adrenoceptor antagonist atenolol into either the hippocampus (1.25 microg in 0.5

180 When ISO plus the beta(1)-AR antagonist atenolol (ISO-beta(2)-AR stimulation) or 1 microM zinter

181 metoprolol (highly permeable compounds) and atenolol (low-moderate permeability compound) were orall

182 95% confidence limits, -61.0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.

183 During summer, atenolol, metoprolol, and propranolol were rapidly atten

184 The fate of three selected beta blockers-atenolol, metoprolol, and sotalol-was examined during ni

185 oval mechanism in the pilot-scale system for atenolol, metoprolol, and trimethoprim, while sulfametho

186 ances were attenuated by at least 60%, five (atenolol, metoprolol, celiprolol, propranolol, and fleca

187 e control during exercise and while at rest: atenolol, metoprolol, diltiazem, and verapamil (drugs li

188 intervals (CIs) for first cardiac events for atenolol, metoprolol, propranolol, and nadolol were 0.71

189 ry who were prescribed common beta-blockers (atenolol, metoprolol, propranolol, or nadolol).

190 rtan (n = 173) than in patients treated with atenolol (n = 254) (relative risk, 0.69 [CI, 0.57 to 0.8

191 to receive once-daily losartan (n = 660) or atenolol (n = 666) with hydrochlorothiazide as the secon

192 e activity (emtricitabine, trimethoprim, and atenolol), nitrous oxide reduction (trimethoprim), ammon

193 lex, beta(2)-AR stimulation (salbutamol plus atenolol) of I(Ca,L) was examined in pertussis toxin-tre

194 a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in t

195 omparison with beta-blockers, the effects of atenolol on cardiovascular hemodynamics were examined, w

196 4-year trial of the effect of lacidipine or atenolol on echographic carotid intima-media thickness.

197 is by comparing the effects of nebivolol and atenolol on endothelial function.

198 astrointestinal therapeutic system (GITS) or atenolol on ischemic left ventricular dysfunction induce

199 the impact of treatment with losartan versus atenolol on outcomes, ECG strain remained a significant

200 ffect of R(+) enantiomers of propranolol and atenolol on the formation of IH-like blood vessels from

201 mg simvastatin, 10 mg lisinopril, and 50 mg atenolol or (2) 75 mg aspirin, 40 mg simvastatin, 10 mg

202 f chlorthalidone (step 1); either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be add

203 verapamil and 8361 received either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide.

204 noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.1

205 curred in the COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR]

206 -verapamil group (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (HR, 1.54

207 nd 7.1 mm Hg for partcipants assigned to the atenolol or hydrochlorothiazide group.

208 ssociation of these loci with BP response to atenolol or hydrochlorothiazide monotherapy in 768 hyper

209 propranolol, and LTM dogs received placebo, atenolol, or amlodipine.

210 g ECG, were treated in a blinded manner with atenolol- or losartan-based regimens, and were followed

211 pertension) treated in a blinded manner with atenolol- or losartan-based regimens.

212 xin (p < 0.0001), diltiazem (p < 0.0002) and atenolol (p < 0.001).

213 delayed with regimens 3 and 5 which included atenolol (p < 0.03).

214 lol (p = 9.9 x 10(-3), beta = 7.47) and PEAR atenolol (p = 0.04, beta = 4.36) for association with DB

215 Losartan decreased ECG-LVH more than atenolol (P<.001) and was better tolerated.

216 ring alleles was associated with response to atenolol (P=3.3 x 10(-6) for systolic BP; P=1.6 x 10(-6)

217 .9 x 10(-4)%/mm Hg [27.5; -77.7 to 30.0] for atenolol; p(overall)=0.019).

218 .1 x 10(-4)%/mm Hg [19.6; -45.5 to 31.1] for atenolol; p(overall)=0.39) but did differ in patients wi

219 that both systemic beta(1)AR antagonism with atenolol (peripherally restricted) and metoprolol (brain

220 e verapamil plus trandolapril) vs B-blocker (atenolol plus hydrochlorothiazide) treatment strategy.

221 ade of peripheral adrenergic B1 receptors by atenolol potently attenuates the elevation in circulatin

222 of peripheral adrenergic beta1 receptors by atenolol potently attenuates the elevation in circulatin

223 Therapy with either nifedipine GITS or atenolol prevented the development of wall-motion abnorm

224 Digoxin + atenolol produced the most effective rate control reflec

225 prolol [RR = 0.46 (95% CI 0.02-11.65)], oral atenolol [RR = 0.51 (95% CI 0.20-1.28)], infusion of pra

226 Our results using atenolol, salbutamol, and cocaine as test compounds show

227 nd evoked atropine-sensitive bradycardia and atenolol-sensitive tachycardia with premature ventricula

228 r to demonstrate enantiomeric separations of atenolol, serine, methionine, threonine, methyl alpha-gl

229 ntrol on captopril, hydrochlorothiazide, and atenolol show a reduction of LV mass after 1 year of tre

230 Flecainide, verapamil and atenolol significantly reduced power output of muscles.

231 The beta1-specific antagonist, atenolol, significantly decreased latency to attack (1 m

232 ol were dose-dependent and not observed with atenolol; similar effects were observed with apocynin, a

233 ere evaluated for five drugs: carbamazepine, atenolol, sulfamethazine, diazepam, and alprazolam.

234 py reduced ischemia further, with amlodipine/atenolol superior to diltiazem (Adizem XL)/isosorbide 5-

235 th persistence of the benefit of losartan vs atenolol therapy on developing AF (HR, 0.83; 95% CI, 0.7

236 Regression of ECG LVH with losartan versus atenolol therapy was assessed in 9193 hypertensive patie

237 Atenolol therapy was associated with lower baseline and

238 impact of 2 different BP lowering-regimens (atenolol+/-thiazide-based versus amlodipine+/-perindopri

239 Quantitative measurements of atenolol, tioconazole, tetraethylammonium bromide, and t

240 ocardiograms in 457 losartan-treated and 459 atenolol-treated participants with > or =1 follow-up mea

241 tients (17.5 per 1000 patient-years) and 355 atenolol-treated patients (21.8 per 1000 patient-years;

242 red in 125 losartan-treated patients and 193 atenolol-treated patients (relative risk, 0.66 [CI, 0.53

243 red in 103 losartan-treated patients and 132 atenolol-treated patients (relative risk, 0.80 [CI, 0.62

244 red in 110 losartan-treated patients and 100 atenolol-treated patients (relative risk, 1.14 [CI, 0.87

245 e hospital was significantly lower among the atenolol-treated patients than among those who were give

246 ar outcomes were similarly reduced among the atenolol-treated patients; event-free survival throughou

247 ment of impaired fasting glucose (IFG) after atenolol treatment.

248 During exercise, digoxin and digoxin + atenolol treatments resulted in the highest and lowest m

249 cin users, 24.0% of metformin users, 6.9% of atenolol users, 6.6% of rosuvastatin users, and 5.8% of

250 Remarkably, zero-order release of atenolol was achieved from FAU (SiO(2):Al(2)O(3) = 80:1)

251 nths of lisinopril therapy, the beta-blocker atenolol was added to lisinopril for another three month

252 When atenolol was added, it rose significantly and returned t

253 Atenolol was begun at a dose of 12.5 mg daily and increa

254 Atenolol was given intravenously before and immediately

255 Biodegradation of atenolol was observed and linked to the activity of ammo

256 Atenolol was observed to competitively inhibit AOB growt

257 The VR on digoxin + atenolol was significantly lower than that on digoxin (p

258 Amlodipine/atenolol was significantly superior during the drug-free

259 Atenolol was transformed almost completely to atenolol a

260 me who were randomly assigned to losartan or atenolol, we found no significant difference in the rate

261 f glyceryl trinitrate (GTN), amlodipine, and atenolol were studied in nine normal volunteers.

262 diltiazem-CD, and 5) 0.25 mg digoxin + 50 mg atenolol; were studied after 2 week treatment assigned i

263 ine, plus adjunctive hydrochlorothiazide and atenolol when needed to control blood pressure, both had

264 Conversely, atenolol, when added to lisinopril, achieved maximum hem

265 was also inhibited by high- but not low-dose atenolol, whereas collagen content was not elevated with

266 were prevented by cotreatment with high-dose atenolol (which nearly fully inhibited isoproterenol-ind

267 and shorter transit distance in contrast to atenolol, which was absorbed more slowly from more dista

268 ol with 2.5 mg of bendrofluazide or 50 mg of atenolol with 2.5 mg of bendrofluazide.

269 om baseline to the last available study than atenolol with adjustment for baseline LVMI and blood pre

270 bo-controlled trial to compare the effect of atenolol with that of a placebo on overall survival and

271 investigated to achieve prolonged release of atenolol, with the release rates determined by the combi